ReviewJournal of oncology2019
From Whole-Brain Radiotherapy to Immunotherapy: A Multidisciplinary Approach for Patients with Brain Metastases from NSCLC.
Review in Journal of oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04835025 (A Retrospective, Multicenter Case-control Study of Radiotherapy Combined With Immunotherapy for Brain Metastases of Non-small Cell Lung Cancer), which is not on this map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Retrospective, Multicenter Case-control Study of Radiotherapy Combined With Immunotherapy for Brain Metastases of Non-small Cell Lung Cancer
Who cites it
13 citing papers in PubMed, 21 citations in OpenAlex.
- Transcranial direct current stimulation enhances cognitive performance and modulates QEEG beta- and theta-band power in patients undergoing whole-brain radiotherapy.IBRO neuroscience reports · 2026Article
- Safety and efficacy of delivering systemic treatments concomitantly with whole-brain radiotherapy: a prospective, observational, single-institution study.Exploration of targeted anti-tumor therapy · 2026Article
- Combination of immunotherapy and whole-brain radiotherapy on prognosis of patients with multiple brain metastases: A retrospective cohort study.Open life sciences · 2025Article
- Immunotherapy in the Battle Against Bone Metastases: Mechanisms and Emerging Treatments.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Using machine learning-based radiomics to differentiate between glioma and solitary brain metastasis from lung cancer and its subtypes.Discover oncology · 2023Article
- Prognostic value of cell-free DNA in cerebrospinal fluid from lung cancer patients with brain metastases during radiotherapy.Radiation oncology (London, England) · 2023Article
- Efficacy and Safety of EGFR Tyrosine Kinase Inhibitors Combined with Cranial Radiotherapy for Brain Metastases from Non-Small-Cell Lung Cancer: A Protocol for a Systematic Review and Meta-Analysis.BioMed research international · 2022Article
- Combination of immunotherapy and radiotherapy in the treatment of brain metastases from non-small cell lung cancer.Journal of thoracic disease · 2021Review
- WBRT for brain metastases from non-small cell lung cancer: for whom and when?-Contemporary point of view.Journal of thoracic disease · 2021Review
- Integration of stereotactic radiosurgery or whole brain radiation therapy with immunotherapy for treatment of brain metastases.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2020Article
- Antibodies for the Treatment of Brain Metastases, a Dream or a Reality?Pharmaceutics · 2020Review
- Histogram analysis of absolute cerebral blood volume map can distinguish glioblastoma from solitary brain metastasis.Medicine · 2019Article
- Metastasis manners and the underlying mechanisms of ALK and ROS1 rearrangement lung cancer and current possible therapeutic strategies.RSC advances · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-small cell lung cancer patients with brain metastases have a multitude of treatment options, but there is currently no international and multidisciplinary consensus concerning their optimal treatment. Local therapies have the principal role, especially in symptomatic patients. Advances in surgery and radiation therapy manage considerable local control. Systemic treatments have shown effect in clinical trials and in real life clinical settings; yet, at present, this is restricted to patients with asymptomatic or stable intracranial lesions. Targeted agents can have a benefit only in patients with EGFR mutations or ALK rearrangement. Immunotherapy has shown impressive results in patients with PD-L1 expression in tumor cells. Its effects can be further enhanced by a synergy with radiotherapy, possibly by increasing the percentage of responders. The present review summarizes the need for more effective systemic treatments, so that the increased intracranial control achieved by local treatments can be translated in an increase in overall survival.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.